# A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

> **NCT07002177** · PHASE1,PHASE2 · RECRUITING · sponsor: **Forward Pharmaceuticals Co., Ltd.** · enrollment: 196 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Breast Cancer Stage I
- Breast Cancer Stage II
- Locally Advanced Breast Cancer (LABC)
- ER+ Breast Cancer

## Interventions

- **DRUG:** FWD1802
- **DRUG:** Palbociclib 125mg
- **DRUG:** Ribociclib 200Mg Oral Tablet
- **DRUG:** Abemaciclib 150 MG
- **DRUG:** Everolimus 10 mg

## Key facts

- **NCT ID:** NCT07002177
- **Lead sponsor:** Forward Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07002177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07002177, "A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07002177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*